BR112023003167A2 - Composições e métodos para doenças neurológicas - Google Patents
Composições e métodos para doenças neurológicasInfo
- Publication number
- BR112023003167A2 BR112023003167A2 BR112023003167A BR112023003167A BR112023003167A2 BR 112023003167 A2 BR112023003167 A2 BR 112023003167A2 BR 112023003167 A BR112023003167 A BR 112023003167A BR 112023003167 A BR112023003167 A BR 112023003167A BR 112023003167 A2 BR112023003167 A2 BR 112023003167A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- genetically modified
- neurological diseases
- modified receptors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068890P | 2020-08-21 | 2020-08-21 | |
| PCT/US2021/046915 WO2022040535A2 (en) | 2020-08-21 | 2021-08-20 | Compositions and methods for neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003167A2 true BR112023003167A2 (pt) | 2023-05-02 |
Family
ID=80350587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003167A BR112023003167A2 (pt) | 2020-08-21 | 2021-08-20 | Composições e métodos para doenças neurológicas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317834A1 (https=) |
| EP (1) | EP4200020A4 (https=) |
| JP (1) | JP2023538130A (https=) |
| KR (1) | KR20230061409A (https=) |
| CN (1) | CN116802201A (https=) |
| AU (1) | AU2021329529A1 (https=) |
| BR (1) | BR112023003167A2 (https=) |
| CA (1) | CA3192604A1 (https=) |
| IL (1) | IL300816A (https=) |
| MX (1) | MX2023002161A (https=) |
| WO (1) | WO2022040535A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117487904B (zh) * | 2023-12-28 | 2024-05-31 | 湖南家辉生物技术有限公司 | Gabrb3基因突变体、突变体蛋白、试剂、试剂盒及应用 |
| CN119331917B (zh) * | 2024-10-28 | 2025-10-17 | 北京爱思益普生物科技股份有限公司 | 能够表达GlyR α1/β型GlyR的细胞株及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL304040B2 (en) * | 2016-07-07 | 2024-09-01 | Hughes Howard Med Inst | Modified ligand-gated ion channels and methods of use |
| US10538571B2 (en) * | 2017-11-27 | 2020-01-21 | Coda Biotherapeutics, Inc. | Compositions and methods for neurological diseases |
| AU2020334147A1 (en) * | 2019-08-21 | 2022-03-31 | Trames Bio, Inc. | Compositions and methods for neurological diseases |
-
2021
- 2021-08-20 IL IL300816A patent/IL300816A/en unknown
- 2021-08-20 WO PCT/US2021/046915 patent/WO2022040535A2/en not_active Ceased
- 2021-08-20 EP EP21859205.3A patent/EP4200020A4/en active Pending
- 2021-08-20 CA CA3192604A patent/CA3192604A1/en active Pending
- 2021-08-20 US US18/022,358 patent/US20240317834A1/en active Pending
- 2021-08-20 JP JP2023512700A patent/JP2023538130A/ja active Pending
- 2021-08-20 KR KR1020237009591A patent/KR20230061409A/ko active Pending
- 2021-08-20 CN CN202180070391.2A patent/CN116802201A/zh active Pending
- 2021-08-20 MX MX2023002161A patent/MX2023002161A/es unknown
- 2021-08-20 AU AU2021329529A patent/AU2021329529A1/en active Pending
- 2021-08-20 BR BR112023003167A patent/BR112023003167A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022040535A3 (en) | 2022-03-31 |
| EP4200020A2 (en) | 2023-06-28 |
| US20240317834A1 (en) | 2024-09-26 |
| AU2021329529A9 (en) | 2025-03-13 |
| EP4200020A4 (en) | 2024-11-20 |
| MX2023002161A (es) | 2023-05-18 |
| CN116802201A (zh) | 2023-09-22 |
| JP2023538130A (ja) | 2023-09-06 |
| KR20230061409A (ko) | 2023-05-08 |
| IL300816A (en) | 2023-04-01 |
| WO2022040535A2 (en) | 2022-02-24 |
| AU2021329529A1 (en) | 2023-04-27 |
| CA3192604A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202408862B (en) | Compositions and methods for neurological diseases | |
| Chan et al. | The use of brief post‐surgical low frequency electrical stimulation to enhance nerve regeneration in clinical practice | |
| Wessel et al. | Non-invasive brain stimulation: an interventional tool for enhancing behavioral training after stroke | |
| Thomas et al. | Human spinal cord injury: motor unit properties and behaviour | |
| CY1123734T1 (el) | Καταστολη συμπληρωματος για βελτιωμενη αναγεννηση νευρου | |
| BR112023003167A2 (pt) | Composições e métodos para doenças neurológicas | |
| Chen et al. | Axon plasticity in the mammalian central nervous system after injury | |
| Knott et al. | Cyclic AMP signaling: a molecular determinant of peripheral nerve regeneration | |
| Silva et al. | Evidence for direct axonal toxicity in vincristine neuropathy | |
| BR112021021921A2 (pt) | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2022008625A (es) | Metodo de diferenciacion de celulas neuronales y composiciones relacionadas y metodos de uso. | |
| Lu et al. | Optogenetic stimulation enhanced neuronal plasticities in motor recovery after ischemic stroke | |
| Ahmad et al. | Optogenetics applications for treating spinal cord injury | |
| EP4591708A3 (en) | Gene therapy for stxbp1 encephalopathy | |
| Zhou et al. | Transcranial direct current stimulation alleviated ischemic stroke induced injury involving the BDNF-TrkB signaling axis in rats | |
| PE20242222A1 (es) | Agentes de interferencia de arn de sarm1 | |
| BR112019003912A2 (pt) | composição, método para criação de um hidrogel, matriz, hidrogel, método para indução da formação ou regeneração de um tecido neuronal, método para tratamento de uma lesão do nervo e método para prevenção ou tratamento de choque neurogênico após lesão do nervo | |
| Vida et al. | The reorganized brain: how treatment strategies for stroke and amblyopia can inform our knowledge of plasticity throughout the lifespan | |
| BR112022002236A2 (pt) | Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas | |
| BR112021021787A2 (pt) | Terapias de combinação | |
| BR112023024465A2 (pt) | Usos de um modulador de somatostatina para o tratamento de doença | |
| Kumar et al. | The emerging role of innate immunity in Alzheimer's disease | |
| WO2023280294A9 (zh) | 用于治疗神经退行性疾病或中枢神经系统损伤的靶点及小分子化合物 | |
| Kokaia et al. | The treatment of neurological diseases under a new light: the importance of optogenetics. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025015501-2 PROTOCOLO 870250064552 EM 25/07/2025 15:14. |